Key result
Both PCC and FVIIa improved thrombin generation and normalized hemostasis time at therapeutic dabigatran levels, though FVIIa was ineffective at supratherapeutic levels.
Why the study?
Does prothrombin complex concentrate or recombinant factor VIIa improve thrombin generation and hemostasis in the presence of dabigatran in preclinical models?
Does prothrombin complex concentrate or recombinant factor VIIa improve thrombin generation and hemostasis in the presence of dabigatran in preclinical models?
PCC and FVIIa can reverse dabigatran-induced anticoagulation in preclinical models, with PCC showing efficacy even at supratherapeutic dabigatran levels.
No takes yet. Share an insight, caveat, or question.
Reversal by PCC or rFVIIa is dose- and concentration-dependent in vitro; leaves open optimal clinical strategies.
Hoffman et al. (2014) studied Dabigatran anticoagulation. Prothrombin complex concentrate (PCC) or recombinant factor VIIa (FVIIa) vs. Dabigatran alone was evaluated on Thrombin generation parameters (rate, peak, total amount, lag) and hemostasis time. Both PCC and FVIIa improved thrombin generation and normalized hemostasis time at therapeutic dabigatran levels, though FVIIa was ineffective at supratherapeutic levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: